Microbiome Modulators Market Trends

Global Microbiome Modulators Market Growth, Size, Trends Analysis- By Product, By Form, By Application, By End Use – Regional Outlook, Competitive Strategies and Segment Forecast to 2035

Published: May-2026	Report ID: HLCA2615	Pages: 1 - 250	Formats^*:
Category : Healthcare

According to SPER Market Research, the Global Microbiome Modulators Market is estimated to reach USD 51.18 billion by 2035 with a CAGR 13.15%.

Introduction and Overview

The report includes an in-depth analysis of the Global Microbiome Modulators Market, including market size and trends, product types, materials, applications, and supplier analysis.

The global Microbiome Modulators Market was valued at USD 14.88 billion in 2025 and is estimated to expand at a CAGR of roughly 13.15% throughout 2035, eventually hitting a valuation of USD 51.18 billion. This surge is largely fueled by a rising public understanding of how internal microbial ecosystems dictate systemic health. These modulators—spanning probiotics, prebiotics, synbiotics, and postbiotics—act as biological regulators that recalibrate the body's microbial communities. They are increasingly utilized to counteract the "gut dysbiosis" caused by modern stressors, processed diets, and heavy antibiotic usage. Beyond basic digestion, these products are linked to boosted immunity, reduced systemic inflammation, and improved metabolic regulation. As the trend toward bespoke, "precision" nutrition accelerates, the market continues to diversify into more specialized health solutions.

By Product:

Based on the product. Probiotics lead the market, sustained by high consumer familiarity and constant breakthroughs in strain stability. Meanwhile, prebiotics and synbiotics are rising in prominence as essential "fuel" for beneficial gut flora. The industry is also seeing a shift toward clinical sophistication, with postbiotics and LBPs gaining traction as technological refinements allow for more targeted therapeutic interventions.

By Form:

The market offers several delivery methods, including capsules, tablets, powders, and liquids. Capsules currently lead the market because they offer the best protection for live cultures, ensuring they survive the journey to the gut. Powders are seeing a spike in interest due to their versatility in functional foods and adjustable dosing. Liquid formats are carving out a specific niche, catering primarily to the pediatric market and aging populations who require easier ingestion and faster nutrient uptake.

By Application:

Key applications range from gastrointestinal (GI) disorders and infectious diseases to oncology and dermatology. GI disorders remain the primary revenue driver, but there is significant momentum in immune regulation and metabolic health. Notably, the use of microbiome modulators as an adjunct to cancer therapy is a burgeoning field, while bacteriophage research is offering promising alternatives to traditional antibiotics in treating resistant infections.

By End Use:

This market spans pharmaceuticals, nutraceuticals, food and beverages, and animal nutrition. The dietary supplement and nutraceutical segment is the frontrunner, fueled by a proactive "wellness-first" consumer mindset. However, the pharmaceutical sector is investing heavily in R&D for medical-grade microbial therapies. Additionally, the animal feed industry is adopting these modulators to phase out growth-promoting antibiotics, favoring more sustainable, biology-based health strategies for livestock.

Regional Insights:

Market expansion is global, with North America leading due to a sophisticated healthcare infrastructure and a massive consumer appetite for preventive supplements. In Europe, Germany remains a central hub for natural health innovation. The Asia-Pacific region is identified as the fastest-growing frontier; rising middle-class incomes and a cultural focus on functional nutrition—particularly in China—are driving rapid adoption. Latin America is also showing steady progress as urbanization shifts consumer focus toward modern wellness trends.

Market Competitive Landscape:

The landscape is characterized by strategic consolidation among industry leaders. Major players shaping the market include AB-Biotics, ADM, BioGaia, Biohm Technologies, DSM-Firmenich, Ferring, Lallemand Health Solutions, Modulate Biosystems, Ritual, Sabinsa Corporation, Second Genome, Inc., TCI Co., Ltd., and 4D Pharma Plc.

Recent Developments:

In November 2024, AstraZeneca committed USD 3.5 billion to bolster its US-based research and production capabilities. This investment is specifically designed to accelerate the development of microbiome-centered medicines and expand their therapeutic reach.
In October 2024, ADM and Biohm Technologies introduced Vivifem, a sophisticated microbiome solution designed for women’s health. By blending pre-, pro-, and postbiotics, the product focuses on healthy aging and personalized wellness, highlighting ADM’s strategic pivot toward data-driven, customized health products.

Scope of the report:

Report Metric	Details
Market size available for years	2021-2034
Base year considered	2024
Forecast period	2025-2034
Segments covered	By Product, By Form, By Application, By End Use
Regions covered	North America, Latin America, Asia-Pacific,Europe, and Middle East &, Africa
Companies Covered	AB-Biotics, SA, ADM, BioGaia, Biohm Technologies, DSM-Firmenich, Ferring, Lallemand Health Solutions, Modulate Biosystems, Ritual, Sabinsa Corporation, Second Genome, Inc., TCI Co., Ltd., 4D Pharma Plc.

Key Topics Covered in the Report

Global Microbiome Modulators Market Size (FY’2022-FY’2035)
Overview of Global Microbiome Modulators Market
Segmentation of Global Microbiome Modulators Market by Product (Probiotics, Prebiotics, Synbiotics, Postbiotics,Live biotherapeutic products (LBPs),Bacteriophage therapies)
Segmentation of Global Microbiome Modulators Market by Form (Capsules, Tablets, Powders, Liquids, Others)
Segmentation of Global Microbiome Modulators Market by Application (Infectious diseases, Gastrointestinal disorders, Immune system disorders, Cancer therapy, Metabolic diseases, Dermatological conditions)
Segmentation of Global Microbiome Modulators Market by End User (Pharmaceutical & biotechnology, Dietary supplements & nutraceuticals, Food & beverage, Animal feed & nutrition, Others)
Statistical Snap of Global Microbiome Modulators Market
Expansion Analysis of Global Microbiome Modulators Market
Problems and Obstacles in Global Microbiome Modulators Market
Competitive Landscape in the Global Microbiome Modulators Market
Details on Current Investment in Global Microbiome Modulators Market
Competitive Analysis of Global Microbiome Modulators Market
Prominent Players in the Global Microbiome Modulators Market
SWOT Analysis of Global Microbiome Modulators Market
Global Microbiome Modulators Market Future Outlook and Projections (FY’2026-FY’2035)
Recommendations from Analyst

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source

2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s

2.2. Market size estimation

2.2.1. Top-down and Bottom-up approach

2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis

4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis

5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats

5.2. PESTEL Analysis

5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape

5.3. PORTER’s Five Forces

5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry

5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Microbiome Modulators Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Microbiome Modulators Market

7. Global Microbiome Modulators Market, By Product, (USD Million) 2022-2035

7.1. Probiotics
7.2. Prebiotics
7.3. Synbiotics
7.4. Postbiotics
7.5. Live biotherapeutic products (LBPs)
7.6. Bacteriophage therapies

8. Global Microbiome Modulators Market, By Form, (USD Million) 2022-2035

8.1. Capsules
8.2. Tablets
8.3. Powders
8.4. Liquids
8.5. Others

9. Global Microbiome Modulators Market, By Application, (USD Million) 2022-2035

9.1. Infectious diseases
9.2. Gastrointestinal disorders
9.3. Immune system disorders
9.4. Cancer therapy
9.5. Metabolic diseases
9.6. Dermatological conditions

10. Global Microbiome Modulators Market, By End Use, (USD Million) 2022-2035

10.1. Pharmaceutical & biotechnology
10.2. Dietary supplements & nutraceuticals
10.3. Food & beverage
10.4. Animal feed & nutrition
10.5. Others

11. Global Microbiome Modulators Market, (USD Million) 2022-2035

11.1. Global Microbiome Modulators Market Size and Market Share

12. Global Microbiome Modulators Market, By Region, (USD Million) 2022-2035

12.1. Asia-Pacific

12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific

12.2. Europe

12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe

12.3. Middle East and Africa

12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa

12.4. North America

12.4.1. Canada
12.4.2. Mexico
12.4.3. United States

12.5. Latin America

12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America

13. Company Profile

13.1. AB-Biotics, SA

13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments

13.2. ADM

13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments

13.3. BioGaia

13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments

13.4. Biohm Technologies

13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments

13.5. DSM-Firmenich

13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments

13.6. Ferring

13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments

13.7. Lallemand Health Solutions

13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments

13.8. Modulate Biosystems

13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments

13.9. Ritual

13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments

13.10. Sabinsa Corporation

13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments

13.11. Second Genome, Inc.

13.11.1. Company details
13.11.2. Financial outlook
13.11.3. Product summary
13.11.4. Recent developments

13.12. TCI Co., Ltd.

13.12.1. Company details
13.12.2. Financial outlook
13.12.3. Product summary
13.12.4. Recent developments

13.13. 4D Pharma Plc

13.13.1. Company details
13.13.2. Financial outlook
13.13.3. Product summary
13.13.4. Recent developments

13.14. Others

14. Conclusion

15. List of Abbreviations

16. Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1